Citi maintains buy rating on Cogent stock ahead of trial results

Cogent Biosciences (COGT) is a focus for investors with Citi, H.C. Wainwright, and Piper Sandler maintaining Buy/Overweight ratings ahead of critical Phase 2 SUMMIT trial results for bezuclastinib in non-advanced systemic mastocytosis, expected in July. Analysts anticipate bezuclastinib could demonstrate superior efficacy and a manageable safety profile versus competitors, with Citi projecting over 50% upside, despite the stock's high Price/Book ratio and noted rapid cash burn. While Q1 2025 net losses were narrower than expected and the company holds $245.7 million in cash, supporting operations into late 2026, the upcoming trial readout is seen as a pivotal catalyst for future valuation.

Analysis

Cogent Biosciences (COGT) is positioned ahead of a pivotal catalyst with the expected July readout of its Phase 2 SUMMIT trial for bezuclastinib. Analyst sentiment is strongly positive, with Citi, Piper Sandler, and H.C. Wainwright all maintaining Buy or Overweight ratings. Citi has placed the stock on a 30-day Upside Catalyst Watch, arguing that the market has mispriced the potential for a successful trial, creating a favorable risk/reward at its current $7.10 price. Their base case projects over 50% upside, contingent on bezuclastinib demonstrating efficacy 75-100% superior to its competitor, Ayvakit, with a manageable safety profile. Financially, the company's Q1 2025 net loss of $0.52 per share was narrower than some forecasts, and it maintains a strong liquidity position with a current ratio of 5.13 and cash reserves of $245.7 million, sufficient to fund operations into late 2026. However, this is offset by significant risks, including a rapid cash burn rate and a high Price/Book ratio of 7.3. The outlook is further supported by two additional pivotal readouts anticipated for other indications later this year.

Key Decisions for Investors

• Investors should view COGT as a high-risk, high-reward opportunity, with valuation heavily dependent on the binary outcome of the Phase 2 SUMMIT trial results for bezuclastinib in July.
• Given the significant cash burn rate and high Price/Book multiple, it is critical to monitor the company's liquidity, even with a cash runway projected into late 2026.
• The primary thesis rests on bezuclastinib's potential superiority over competitor Ayvakit; therefore, the key metrics to scrutinize in the upcoming data release will be the specific efficacy and safety profiles versus this benchmark.
• Consider the stock's positioning ahead of the July catalyst, as analysts believe a successful outcome is not fully priced in, but also note the two additional pivotal readouts later this year which provide further potential catalysts.